An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Prescription rates for the big weight-loss drugs semaglutide and tirzepatide are rising and look set to keep growing through 2025, according to business coverage. In plain terms: more doctors are writing prescriptions for these medicines now than a few years ago, and that increase is expected to continue as more people use them for weight loss and related health issues. Semaglutide and tirzepatide are medicines based on peptides, which are tiny chains of amino acids — think of them as small, simple proteins. Semaglutide is the active ingredient in brand-name drugs like Ozempic and Wegovy. It acts like a gut hormone that tells your brain you’re full and slows how fast your stomach empties. Tirzepatide is newer and influences two different gut-related hormone signals, so it can reduce appetite and change how the body handles sugar and fat. Both are usually given by injection and were developed originally to treat diabetes; companies later tested and approved higher-dose versions for weight loss. The business story isn’t a scientific trial; it’s about prescribing patterns and market trends. Reports cite rising prescription numbers and projections for continued growth through 2025. That rise reflects factors like growing public interest in these drugs for weight loss, more doctors willing to prescribe them, and new approvals or marketing. The coverage doesn’t claim a sudden medical breakthrough — it’s an economic and health-care trend piece. The underlying clinical studies that got these drugs approved do show meaningful average weight loss in people, but the business articles focus on sales and usage rather than new clinical data. This matters because wider use of these drugs could change how society manages obesity and related conditions like type 2 diabetes. For individuals struggling with weight, increased availability and more prescribing might mean better access to effective treatments. For health systems and insurers, it raises questions about cost, coverage, and long-term care strategies. Employers and policymakers may also pay attention because large shifts in prescription use affect budgets and public health planning. There are important caveats and risks. These drugs can cause side effects such as nausea, diarrhea, constipation, and sometimes more serious problems. They usually require ongoing treatment to maintain weight loss; stopping the drug often leads to weight regain. Not everyone is a candidate — people with certain medical histories or pregnant people should not use them. Insurance coverage is variable, and long-term safety beyond a few years is still being studied. The business reports talk about prescriptions and money flow, not definitive long-term health outcomes, so caution is warranted. Bottom line: prescriptions for semaglutide and tirzepatide are climbing and likely to keep rising through 2025, reflecting real demand and interest, but broader questions about access, long-term safety, side effects, and costs remain.
Source: BusinessWorld Online